Patents Assigned to HEDGEHOG, INC.
  • Endothelin receptor type a activity regulating antibody
    Patent number: 12227566
    Abstract: The present invention relates to a monoclonal antibody or a fragment thereof that recognizes and binds specifically to the extracellular domain of endothelin receptor type A as an antigen. The monoclonal antibody of the present invention is suitable for use in a therapeutic agent for hypertension or cancer associated with endothelin receptor type A.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: February 18, 2025
    Assignee: HEDGEHOG, INC.
    Inventors: Sang Taek Jung, Yeon Gyu Yu, Man-Seok Ju, Jung-Hyun Na, Youn Jae Kim, Hye-Mi Ahn, Byoung Joon Ko, Won Kyu Lee
  • Epitope specific to SMO protein, antibody recognizing same, and composition comprising same
    Patent number: 12091453
    Abstract: The present invention identifies the influence of the TGF?/Smad3/SMO molecular mechanism in cancer cells and elucidates that a high expression level of SMO is associated with the overall survival rate of cancer patients, demonstrating that SMO is a potential prognostic marker for cancer. The present invention relates to a specific epitope of SMO as an antigen and an antibody or a fragment thereof recognizing and binding specifically to the epitope. Therefore, the antibody of the present invention is expected to be useful as a therapeutic agent for SMO-related cancers.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: September 17, 2024
    Assignee: HEDGEHOG, INC.
    Inventors: Sang Cheul Oh, Dae-Hee Lee
  • ANTIBODY WITH ENHANCED BINDING AFFINITY FOR ENDOTHELIN RECEPTOR TYPE A
    Publication number: 20220235140
    Abstract: The present invention relates to an antibody or an antigen-binding fragment thereof that has improved binding affinity for endothelin receptor type A. The present invention also relates to an antibody or an antigen-binding fragment thereof that has improved productivity. The antibody developed in the present invention is suitable for use in the treatment and diagnosis of diseases associated with endothelin receptor type A due to its remarkably improved binding affinity for the antigen and high productivity compared to conventional antibodies.
    Type: Application
    Filed: May 27, 2020
    Publication date: July 28, 2022
    Applicant: HEDGEHOG, INC.
    Inventors: Sang Taek JUNG, Youn Jae KIM, Hye-Mi AHN, Byoung Joon KO, Won Kyu LEE, Jung-Hyun NA, Man-Seok JU
  • EPITOPE SPECIFIC TO SMO PROTEIN, ANTIBODY RECOGNIZING SAME, AND COMPOSITION COMPRISING SAME
    Publication number: 20220213185
    Abstract: The present invention identifies the influence of the TGF?/Smad3/SMO molecular mechanism in cancer cells and elucidates that a high expression level of SMO is associated with the overall survival rate of cancer patients, demonstrating that SMO is a potential prognostic marker for cancer. The present invention relates to a specific epitope of SMO as an antigen and an antibody or a fragment thereof recognizing and binding specifically to the epitope. Therefore, the antibody of the present invention is expected to be useful as a therapeutic agent for SMO-related cancers.
    Type: Application
    Filed: July 11, 2019
    Publication date: July 7, 2022
    Applicant: HEDGEHOG, INC.
    Inventors: Sang Cheul OH, Dae-Hee LEE
  • ENDOTHELIN RECEPTOR TYPE A ACTIVITY REGULATING ANTIBODY
    Publication number: 20220153831
    Abstract: The present invention relates to a monoclonal antibody or a fragment thereof that recognizes and binds specifically to the extracellular domain of endothelin receptor type A as an antigen. The monoclonal antibody of the present invention is suitable for use in a therapeutic agent for hypertension or cancer associated with endothelin receptor type A.
    Type: Application
    Filed: December 5, 2019
    Publication date: May 19, 2022
    Applicant: HEDGEHOG, INC.
    Inventors: Sang Taek JUNG, Yeon Gyu YU, Man-Seok JU, Jung-Hyun NA, Youn Jae KIM, Hye-Mi AHN, Byoung Joon KO, Won Kyu LEE